More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome--sub-analysis of JAPAN-ACS study.
暂无分享,去创建一个
M. Matsuzaki | T. Hiro | Takeshi Kimura | H. Daida | Y. Ozaki | T. Morimoto | M. Yamagishi | H. Arai | Y. Nakagawa | S. Saito | K. Miyauchi | Tetsu Yamaguchi | K. Kimura | T. Yamaguchi | Kazuo Kimura
[1] O. Faergeman,et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.
[2] M. Ezekowitz,et al. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. , 2005, European heart journal.
[3] Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.
[4] Takafumi Hiro,et al. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). , 2009, Circulation journal : official journal of the Japanese Circulation Society.
[5] T. Funahashi,et al. Goals of dyslipidemia management. , 2007, Journal of atherosclerosis and thrombosis.
[6] Katsumi Miyauchi,et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin , 2009, Journal of the American College of Cardiology.
[7] S. Grundy,et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[8] V. Vaccarino,et al. Usefulness of serum high-density lipoprotein cholesterol level as an independent predictor of one-year mortality after percutaneous coronary interventions. , 2009, American Journal of Cardiology.
[9] K. Shimada,et al. Early Statin Treatment in Patients With Acute Coronary Syndrome: Demonstration of the Beneficial Effect on Atherosclerotic Lesions by Serial Volumetric Intravascular Ultrasound Analysis During Half a Year After Coronary Event: The ESTABLISH Study , 2004, Circulation.
[10] Bruce R. Brodie,et al. Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis A Randomized Controlled Trial , 2004 .
[11] M. Matsuzaki,et al. Diabetes mellitus is a major negative determinant of coronary plaque regression during statin therapy in patients with acute coronary syndrome--serial intravascular ultrasound observations from the Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome Trial (the JAPAN-ACS Tria , 2010, Circulation journal : official journal of the Japanese Circulation Society.
[12] Raimund Erbel,et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. , 2006, JAMA.
[13] H. Iso,et al. Measurement performance of reagent manufacturers by Centers for Disease Control and Prevention/Cholesterol Reference Method Laboratory Network lipid standardization specified for metabolic syndrome-focused health checkups program in Japan. , 2009, Journal of atherosclerosis and thrombosis.
[14] Michael Miller,et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. , 2009, The New England journal of medicine.
[15] J. Liao. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. , 2008, Current atherosclerosis reports.
[16] Tian Xiao-yan. Intensive lipid-lowering effect of atorvastatin treatment in patients with acute coronary , 2010 .
[17] J. LeLorier,et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.
[18] R. Collins,et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.
[19] M. Matsuzaki,et al. Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS): rationale and design. , 2006, Circulation journal : official journal of the Japanese Circulation Society.
[20] M. Ezekowitz,et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. , 2001, JAMA.
[21] Stephen J. Nicholls,et al. Application of intravascular ultrasound in anti-atherosclerotic drug development , 2006, Nature reviews. Drug discovery.